assignment
Recruiting

Evaluation of Cryopreserved Autologous CD34+ Cells Transduced with Lentiviral Vector Encoding WAS cDNA in Wiskott-Aldrich Syndrome Patients

Trial ID
2024-517792-20-00
Protocol
OTL-103-4

Register record, history and transparency: CTIS.eu

Trial statistics

science
6
test molecules
location_city
1
research site
public
1
country
medical_information
1
disease
person_search
1
investigator

Diseases & Conditions

Immunodeficiency

Objectives

The primary objective of this clinical study is to evaluate the **clinical efficacy** of the cryopreserved formulation of OTL-103 in subjects with **Wiskott-Aldrich Syndrome**. This evaluation focuses on the reduction of bleeding events at 12 months and the incidence of severe infections from 6 to 18 months. The clinical relevance of this objective lies in its potential to improve patient outcomes by reducing the frequency and severity of these critical complications associated with the syndrome.

Secondary objectives include:

  • Evaluating overall survival at 12, 24, and 36 months.
  • Assessing engraftment at 6 months.
  • Determining the safety of treatment with OTL-103.
  • Evaluating the biological efficacy of the cryopreserved formulation of OTL-103 at 12 months, 2 years, and 3 years.
  • Assessing the clinical efficacy of the cryopreserved formulation of OTL-103 at 2 and 3 years.
  • Evaluating sustained engraftment of the cryopreserved formulation of OTL-103 at 2 and 3 years.
  • Assessing immunological function after treatment with OTL-103 up to 3 years.
  • Evaluating the effect of OTL-103 on health-related quality of life at 1, 2, and 3 years.

Participants

The clinical trial involves a total of **one** participant diagnosed with **Wiskott-Aldrich Syndrome**. The study population is exclusively male, with an age range that includes children and adolescents. Participants were selected based on a confirmed diagnosis of Wiskott-Aldrich Syndrome, characterized by a genetic mutation and specific clinical criteria. The trial does not include a vulnerable population, and no female subjects are involved. Lifestyle considerations such as diet, physical activity, or habits are not specified in the available data. The selection criteria ensure that participants have no human leukocyte antigen-identical related donor available, which is a significant factor in the inclusion process.

Plans and Procedures

The clinical trial is designed to evaluate the efficacy and safety of a **cryopreserved formulation** of OTL-103 in subjects diagnosed with **Wiskott-Aldrich Syndrome**. This is a Phase III, single-arm, open-label study. The trial aims to assess the clinical efficacy of OTL-103 at 12 months for bleeding events and from 6 to 18 months for severe infections. The primary endpoints include the annualized rate of severe infections from 6 to 18 months post-gene therapy compared to one year prior, and the annualized rate of moderate and severe bleeding episodes up to one year post-gene therapy compared to one year prior. Secondary endpoints focus on overall survival at 12, 24, and 36 months, safety and tolerability, absence of malignancy or abnormal clonal proliferation, absence of replication-competent lentivirus, engraftment at 6 months, and biological correlates of efficacy at 12 months, 2 years, and 3 years.

The trial is expected to run until December 31, 2027, with recruitment having commenced on January 8, 2019. Participants will be involved in the study for a period that includes multiple visits. The sequence of study visits begins with an inclusion (screening) visit to confirm eligibility based on criteria such as genetic mutation and clinical score. Follow-up visits will be scheduled to monitor the participants' response to the treatment and to collect data on the primary and secondary endpoints. The end-of-study visit will conclude the participant's involvement, ensuring all necessary data is collected and any remaining health concerns are addressed.

Participants are expected to remain in the study for the full duration unless specific conditions necessitate early termination. These conditions may include the occurrence of severe adverse events, withdrawal of consent, or any other medical reasons deemed significant by the investigators. The study employs a rigorous methodology to ensure the reliability and validity of the results, with a focus on maintaining participant safety and data integrity throughout the trial.

Treatment

The clinical trial involves the administration of several **experimental medications** and auxiliary treatments. The primary investigational product is **OTL-103**, a dispersion for infusion containing the active substance **etuvetidigene autotemcel**. This advanced therapy medicinal product (ATMP) is composed of autologous CD34+ hematopoietic stem cells transduced ex vivo with a lentiviral vector encoding the human Wiskott-Aldrich syndrome gene. OTL-103 is administered via **intravenous administration** with a maximum total dose of 30,000,000 units over a treatment period of one day.

**Fludarabine phosphate** is used as an auxiliary treatment in the form of a concentrate for solution for injection/infusion. It is administered through **intravenous infusion** with a maximum daily and total dose of 30 mg/m² over a period of two days. This chemical-origin active substance is utilized to support the primary investigational product.

**Lenograstim**, another auxiliary treatment, is provided as a powder and solvent for solution for injection/infusion. It is administered subcutaneously with a maximum daily and total dose of 12.5 µg/kg over one day. Lenograstim is a protein-based substance used to enhance the efficacy of the primary treatment.

**Busulfan** is administered as a concentrate for solution for infusion via **intravenous infusion**. The maximum daily dose is 1.2 mg/kg, with a total dose of 9.6 mg/kg over a two-day period. This chemical-origin substance is included to facilitate the primary treatment's effectiveness.

**Rituximab** is provided as a concentrate for solution for infusion and is administered through **intravenous infusion**. The maximum daily and total dose is 375 mg/m² over one day. Rituximab is used as an auxiliary treatment to support the investigational product.

**Plerixafor** is administered as a solution for injection via subcutaneous injection. The maximum daily and total dose is 0.24 mg/kg over one day. This chemical-origin substance is included as an auxiliary treatment to enhance the primary investigational product's efficacy.

Participant compliance with the dosing schedules is monitored throughout the trial to ensure adherence to the treatment protocol. The trial aims to evaluate the clinical efficacy of the investigational product and its auxiliary treatments in subjects with Wiskott-Aldrich Syndrome.

Efficacy

The efficacy of the clinical trial will be assessed through a series of primary and secondary endpoints. The primary endpoints focus on evaluating the clinical efficacy of the cryopreserved formulation of OTL-103 in subjects with **Wiskott-Aldrich Syndrome**. This will be measured by the annualized rate of severe infections from 6 to 18 months after gene therapy compared with the year prior to gene therapy, as well as the annualized rate of moderate and severe bleeding episodes up to 1 year after gene therapy compared with the year prior to gene therapy.

Secondary endpoints include the evaluation of overall survival at 12, 24, and 36 months, and the safety of the treatment, which will be assessed through adverse event reporting, the absence of malignancy or abnormal clonal proliferation due to insertional oncogenesis, and the absence of replication-competent lentivirus. Additionally, the engraftment will be evaluated at 6 months, and biological correlates of efficacy will be assessed at 12 months, 2 years, and 3 years. These assessments will provide a comprehensive understanding of the treatment's efficacy and safety over the specified timeframes.

Inclusion and Exclusion Criteria

check_circle

Inclusion Criteria

  • Diagnosis of WAS defined by genetic mutation and at least one of the following criteria: severe WASP mutation; absent WASP expression; severe clinical score (Zhu clinical score ≥ 3); • No human leukocyte antigen (HLA)-identical related donor available.
cancel

Exclusion Criteria

  • End-organ dysfunction, severe active infection not responsive to treatment, or other severe disease or clinical condition which, in the judgment of the investigator, would make the subject inappropriate for entry into this study. • Malignant neoplasia (except local skin cancer) or a documented history of hereditary cancer syndrome (detected via medical history check during screening). Subjects with a prior successfully treated malignancy and a sufficient follow-up to exclude recurrence (based on oncologist opinion) can be included after discussion and approval by the Medical Monitor. • Myelodysplasia, cytogenetic alterations characteristic of myelodysplastic syndrome and acute myeloid leukemia, or other serious hematological disorders. • Prior allogeneic hematopoietic stem cell transplantation, with evidence of residual cells of donor origin. • Previous gene therapy. • Documented human immunodeficiency virus (HIV) infection (positive HIV ribonucleic acid and/or anti-p24 antibodies).

Trial Status by Country

Country Status Start of Recruitment Planned Patients
Italy ItalyRecruiting08 Jan 20199

Sites & Investigators

Investigational Products

Details about the medicinal products being studied in this clinical trial.

Product Name Role in Trial Formulation Administration Max Daily Dose Treatment Duration EU MP Number
RITUXIMAB
Other—INTRAVENIOUS INFUSION3751SUB12570MIG
PLERIXAFOR
Other—SUBCUTANEOUS INJECTION0.241SUB28849
OTL-103
TestDISPERSION FOR INFUSIONINTRAVENOUS ADMINISTRATION300000001PRD11510701
FLUDARABINE PHOSPHATE
Other—INTRAVENOUS INFUSION302SUB13897MIG
LENOGRASTIM
Other—SUBCUTANEOUS12.51SUB02888MIG
BUSULFAN
Other—INTRAVENIOUS INFUSION1.22SUB05993MIG

Conditions Studied in This Trial

Interventions Studied in This Trial

vaccines
Fludarabine Phosphate
81 trials

Also investigated for

Acute myeloid leukaemia 17Acute lymphocytic leukaemia 7Systemic lupus erythematosus 6B-cell lymphoma 4
vaccines
Lenograstim
8 trials

Also investigated for

Acute lymphocytic leukaemia 1Germ cell cancer 1Immunodeficiency 1Mucopolysaccharidosis I 1
vaccines
Plerixafor
13 trials

Also investigated for

Sickle cell anaemia 4Thalassaemia beta 3Mucopolysaccharidosis I 2Thalassaemia 2
vaccines
Rituximab
201 trials

Also investigated for

Diffuse large B-cell lymphoma 31Follicular lymphoma 17Chronic lymphocytic leukaemia 14Mantle cell lymphoma 13
vaccines
Busulfan
29 trials

Also investigated for

Acute myeloid leukaemia 6Sickle cell anaemia 4Myelodysplastic syndrome 3Thalassaemia beta 3
vaccines
Etuvetidigene Autotemcel
3 trials

Also investigated for

Wiskott-Aldrich syndrome 2Immunodeficiency 1